

Prof. AZMİ YERLİKAYA

Personal Information

Email: azmi.yerlikaya@ksbu.edu.tr

Web: <https://avesis.ksbu.edu.tr/azmi.yerlikaya>

Address: Kütahya Sağlık Bilimleri Üniversitesi Tıp Fakültesi Tıbbi Biyoloji ABD Evliya Çelebi Yerleşkesi Tavşanlı Yolu 10. Km Kütahya, Türkiye

Biography

Dr. Azmi Yerlikaya graduated from the Department of Biology, Science Faculty of Hacettepe University in 1990. In 1996, he received his M.Sc. degree from Drexel University, Philadelphia, USA. He obtained his Ph.D. degree from Hershey Medical Center of Pennsylvania State University in 2002. During Ph.D. studies, he worked on the degradation mechanisms of a short-lived protein S-adenosylmethionine decarboxylase, a polyamine biosynthetic enzyme. He currently works at the Faculty of Medicine, Department of Medical Biology, Kütahya Health Sciences University, Turkey. Dr. Yerlikaya carries out research in cancer biology and molecular biology. One of his current research is focused on the development of proteasome inhibitors-resistant cell lines.

Education Information

Doctorate, Pennsylvania State University, Cellular And Molecular Physiology, United States Of America 1997 - 2002

Post Graduate, Drexel University, Art and Science, Bioscience and Biotechnology, United States Of America 1994 - 1996

Under Graduate, Hacettepe Üniversitesi, Fen Fakültesi, Biyoloji Bölümü, Turkey 1986 - 1990

Foreign Languages

English, C1 Advanced

Certificates, Courses and Trainings

Project Management, Proje Yürütücüleri Proje Yönetimi, Proje yöntemi ile ilgili bilimsel ve mali konular, TÜSSİDE, TÜBİTAK, 2006

IT, Microsoft Word version 2002, Microsoft Word program kullanımı sertifikası, Kütahya Dumlupınar Üniversitesi, 2005

Dissertations

Doctorate, Mechanism of S-Adenosylmethionine Decarboxylase Degradation and Changes in Substrate SAM Level Following Inhibition of the 26S Proteasome, Pennsylvania State University, Cellular And Molecular Physiology, 2002

Research Areas

Health Sciences, Natural Sciences

Academic Titles / Tasks

Professor, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2018 - Continues
Professor, Kütahya Dumlupınar University, School Of Medicine, 2016 - 2018
Associate Professor, Dumlupınar Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2013 - 2016
Associate Professor, Dumlupınar Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Bölümü, 2010 - 2013
Assistant Professor, Dumlupınar Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Bölümü, 2004 - 2010

Professional Experience

Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2016 - Continues
Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2016 - Continues
Head of Department, Kütahya Dumlupınar University, School Of Medicine, 2013 - 2018
Deputy Head of Department, Kütahya Dumlupınar University, Faculty Of Arts And Sciences, 2004 - 2013

Advising Theses

YERLİKAYA A., Proteozom inhibitörü bortezomib ve cisplatin'nin 4t1 kanser hücrelerindeki etkileri, Post Graduate, R.UZUN(Student), 2018
YERLİKAYA A., Bortezomib ve BAPTA kombinasyonunun 4T1 fare meme kanseri hücrelerinde çeşitli sinyal iletim yolları üzerindeki etkisi, Post Graduate, Ş.YERLİKAYA(Student), 2016
YERLİKAYA A., Prokaryotlarda ubiquitin benzeri proteinlerin biyoinformatik yöntemlerle belirlenmesi, Post Graduate, E.ŞENOL(Student), 2015
YERLİKAYA A., GRP78 inhibitörü bapta ve velcade kombinasyonunun 4T1 hücre kültürü üzerindeki etkilerinin in vitro belirlenmesi, Post Graduate, E.ERDOĞAN(Student), 2014
Yerlikaya A., Canbek M., Sıçanlarda parsiyel hepatektomi sonrası karaciğer rejenerasyonuna geraniolün etkisinin NF- κ B yolağı üzerinden belirlenmesi, Doctorate, E.CEYHAN(Student), 2013
YERLİKAYA A., Proteozom İnhibisyonu Uyarılan Bazı Kanser Hücre Hatlarının Proteomik Analizleri, Doctorate, E.OKUR(Student), 2013
YERLİKAYA A., 5-fluorouracil ve proteozom inhibitörü bortezomib'in 4T1 meme kanseri hücrelerindeki etkileri, Post Graduate, F.ZEHRA(Student), 2013
YERLİKAYA A., Proteozom inhibitörü PS-341 ve HSP70 inhibitörü quercetin'in B16F10 hücre kültürüne etkileri, Post Graduate, S.ŞEKER(Student), 2010
YERLİKAYA A., Proteozom inhibisyonunun 4T1 meme ve B16F10 melanoma hücrelerindeki apoptotik etkilerinin araştırılması, Post Graduate, E.OKUR(Student), 2010
YERLİKAYA A., Proteozom inhibitörü MG-132'nin kanser hücre dizilerine etkisi, Post Graduate, H.DOKUDUR(Student), 2009

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.**
Yerlikaya A., Kanbur E., Stanley B. A. , Tümer E.
Anti-cancer agents in medicinal chemistry, vol.21, pp.20-32, 2021 (Journal Indexed in SCI Expanded)
- II. **The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.**
Yerlikaya A., Kanbur E.
Current drug targets, 2020 (Journal Indexed in SCI Expanded)
- III. **An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in**

PC3 prostate cancer cell line

Yerlikaya A., Okur E.

CYTOTECHNOLOGY, vol.72, no.1, pp.121-130, 2020 (Journal Indexed in SCI)

- IV. **A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis**
Okur E., Yerlikaya A.
CELL BIOLOGY AND TOXICOLOGY, vol.35, no.1, pp.33-47, 2019 (Journal Indexed in SCI)
- V. **Secretomes reveal several novel proteins as well as TGF-beta 1 as the top upstream regulator of metastatic process in breast cancer**
ERİN N., Ogan N., YERLİKAYA A.
BREAST CANCER RESEARCH AND TREATMENT, vol.170, no.2, pp.235-250, 2018 (Journal Indexed in SCI)
- VI. **Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line**
DÜZGÜN Ş. A. , YERLİKAYA A., ZEREN S., BAYHAN Z., OKUR E., BOYACI İ.
CYTOTECHNOLOGY, vol.69, no.4, pp.711-724, 2017 (Journal Indexed in SCI)
- VII. **A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib**
YERLİKAYA A., Erdoğan E., OKUR E., Yerlikaya Ş., SAVRAN B.
ONCOLOGY LETTERS, vol.12, no.1, pp.323-330, 2016 (Journal Indexed in SCI)
- VIII. **Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.**
Aras B., Yerlikaya A.
Oncology letters, vol.11, pp.3179-3184, 2016 (Journal Indexed in SCI Expanded)
- IX. **A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line**
YERLİKAYA A., OKUR E., BAYKAL A. T. , Acilan C., BOYACI İ., ULUKAYA E.
JOURNAL OF PROTEOMICS, vol.113, pp.315-325, 2015 (Journal Indexed in SCI)
- X. **Data for a proteomic analysis of p53 independent induction of apoptosis by bortezomib**
YERLİKAYA A., OKUR E., BAYKAL A. T. , Acilan C., BOYACI İ., ULUKAYA E.
DATA IN BRIEF, vol.1, pp.56-59, 2014 (Journal Indexed in SCI Expanded)
- XI. **Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro**
ULUKAYA E., Sarimahmut M., CEVATEMRE B., Ari F., YERLİKAYA A., Dimas K.
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.4, pp.477-482, 2014 (Journal Indexed in SCI)
- XII. **Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells**
SAVRAN B., YERLİKAYA A., Erdoğan E., GENÇ O.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.14, no.3, pp.466-472, 2014 (Journal Indexed in SCI)
- XIII. **Evaluation of whether the ACE gene I/D polymorphism constitutes a risk factor for chronic obstructive pulmonary disease in the Turkish population**
AYADA C., TORU Ü., GENÇ O., YERLİKAYA A., ŞAHİN S., TURGUT S., TURGUT G.
GENETICS AND MOLECULAR RESEARCH, vol.13, no.4, pp.10427-10433, 2014 (Journal Indexed in SCI)
- XIV. **Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16f10 melanoma cell line**
Koçak F. E. , Erdoğan E., Özyiğit F., Yerlikaya A.
Cellular And Molecular Biology, vol.59, pp.1894-1898, 2013 (Journal Indexed in SCI Expanded)
- XV. **The Significance of Ubiquitin Proteasome Pathway in Cancer Development**
YERLİKAYA A., Yontem M.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, vol.8, no.3, pp.298-309, 2013 (Journal Indexed in SCI)
- XVI. **Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells**
YERLİKAYA A., Altikat S., Irmak R., Cavga F. Z. , Kocacan S., BOYACI İ.
MOLECULAR MEDICINE REPORTS, vol.8, no.1, pp.277-281, 2013 (Journal Indexed in SCI)

- XVII. **Expression of Heme Oxygenase-1 in Response to Proteasomal Inhibition**
YERLİKAYA A.
PROTEIN AND PEPTIDE LETTERS, vol.19, no.12, pp.1330-1333, 2012 (Journal Indexed in SCI)
- XVIII. **The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib**
YERLİKAYA A., OKUR E., ULUKAYA E.
TUMOR BIOLOGY, vol.33, no.5, pp.1385-1392, 2012 (Journal Indexed in SCI)
- XIX. **Investigation of the eIF2 alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells**
Yerlikaya A., Dokudur H.
MOLECULAR BIOLOGY, vol.44, no.5, pp.760-768, 2010 (Journal Indexed in SCI)
- XX. **Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line**
YERLİKAYA A., OKUR E., Seker S., ERİN N.
MOLECULAR MEDICINE REPORTS, vol.3, no.2, pp.333-339, 2010 (Journal Indexed in SCI)
- XXI. **Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade**
YERLİKAYA A., ERİN N.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol.22, no.6, pp.817-823, 2008 (Journal Indexed in SCI)
- XXII. **Phosphorylation of eIF2 alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase**
YERLİKAYA A., Kimball S., Stanley B. A.
BIOCHEMICAL JOURNAL, vol.412, pp.579-588, 2008 (Journal Indexed in SCI)
- XXIII. **Variations in fatty acids composition of pikeperch (Sander lucioperca) liver with respect to gonad maturation**
UYSAL K., YERLİKAYA A., Aksoylar M., YÖNTEM M., ULUPINAR M.
ECOLOGY OF FRESHWATER FISH, vol.15, no.4, pp.441-445, 2006 (Journal Indexed in SCI)
- XXIV. **Structural basis for the inactivation of AdoMetDC K12R mutant**
YERLİKAYA A., Stanley B. A.
PROTEIN AND PEPTIDE LETTERS, vol.13, no.3, pp.313-317, 2006 (Journal Indexed in SCI)
- XXV. **S-Adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination**
YERLİKAYA A., Stanley B. A.
JOURNAL OF BIOLOGICAL CHEMISTRY, vol.279, no.13, pp.12469-12478, 2004 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Proteozom inhibitörü MG132 nin 4T1 meme ve B16F10 melanoma kanser hücrelerindeki sitotoksik etkileri**
YERLİKAYA A., Dokudur H., Şeker S.
Dumlupınar Üniversitesi Fen Bilimleri Dergisi, vol.19, pp.15-22, 2009 (Other Refereed National Journals)
- II. **Protein yıkımının önemi**
YERLİKAYA A., Dokudur H.
Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.35, pp.93-99, 2009 (Other Refereed National Journals)
- III. **Polyamines and S adenosylmethionine decarboxylase a polyamine biosynthetic enzyme**
YERLİKAYA A.
Turkish Journal of Biochemistry, vol.29, pp.208-214, 2004 (Refereed Journals of Other Institutions)
- IV. **Cellular functions of the 26S proteasome**
YERLİKAYA A.
Turkish Journal of Biology, vol.28, pp.31-38, 2004 (Refereed Journals of Other Institutions)

Books & Book Chapters

- I. **Bölüm G - Beyin**
YERLİKAYA A.
in: İnsan Fizyolojisi, Addurrahman Aktümsek, Editor, Nobel Yayınevi, pp.193-232, 2010
- II. **Protein sentezi ve yıkımı**
YERLİKAYA A.
in: Moleküler Biyoloji, Ahmet Yıldırım, Fevzi Bardakçı, Mehmet Karataş, Bahattin Tanyolaç, Editor, Nobel Yayınevi, pp.219-246, 2007

Refereed Congress / Symposium Publications in Proceedings

- I. **26S Proteozom İnhibitörü Bortezomibe Dirençli Prostat Hücre Hattı ve Direnç Mekanizmaları**
Kanbur E., Tümer E., Budak F., Yerlikaya A.
25. Ulusal İmmünoloji Kongresi, Bursa, Turkey, 20 - 22 November 2020, pp.5-6
- II. **Proteozom inhibitörü carfilzomib'in vinkristin ve karboplatin ile Y79 retinoblastom hücre hattı üzerindeki in vitro etkinliklerinin karşılaştırılması.**
AKTAŞ S., OKUR E., YERLİKAYA A., AKTAŞ H., ÖZCURA F.
TOD 51. Ulusal Oftalmoloji Kongresi, Turkey, 24 - 29 October 2017
- III. **Kanser Araştırmalarında Proteomik Yaklaşımlar, Deneysel Modeller ve Getirileri**
YERLİKAYA A., OKUR E.
24. Ulusal Farmakoloji Kongresi, Turkey, 17 - 20 October 2017
- IV. **Comparisons of metastatic and non-metastatic breast carcinoma cells using proteomic analysis of exosomes reveals increased secretion of BMP-1, fibulin4 and TGF-B1**
Ogan N., YERLİKAYA A., ERİN N.
3rd Congress of the Serbian Association for Cancer Research, Belgrade, Serbia And Montenegro, 6 - 07 October 2017, pp.55-56
- V. **Proteozom İnhibitörü Bortezomibe Dirençli Prostat PC-3 Kanseri Hücresi**
YEŞİLMEN B., YERLİKAYA A., OKUR E.
17. ULUSAL MARMARA ÜNİVERSİTESİ TIP ÖĞRENCİ KONGRESİ, Turkey, 12 - 14 May 2017
- VI. **Increased Expression of TGF 1 and TSLP in Highly Metastatic Breast Cancer Cell Lines**
Yitiz N., YERLİKAYA A., ERİN N.
6. Multidisipliner Kanser Araştırma Kongresi, Konya, Turkey, 27 - 30 October 2016
- VII. **Effects of p38 MAP kinase inhibitors on MDA MB 231 cell line**
DÜZGÜN Ş. A. , YERLİKAYA A., ZEREN S., BAYHAN Z., OKUR E.
41st FEBS Congress, 3 - 08 September 2016
- VIII. **Comparisons of metastatic and non metastatic breast carcinoma cells using proteomic analysis of exosomes**
ERİN N., YERLİKAYA A.
41st FEBS Congress, 3 - 08 September 2016
- IX. **The effect of season on liver fatty acids of pikeperch Sander lucioperca from lake Eğirdir Turkey**
UYSAL K., YERLİKAYA A., Aksoylar M., YÖNTEM M., ULUPINAR M.
II: International Natural Protection Symposium, 8 - 10 September 2005
- X. **Apoptotic mechanism of a new combination involving bortezomib and GRP78 inhibitor BAPTA on 4T1 cancer cells**
Yerlikaya Ş., OKUR E., YERLİKAYA A.
3rd Anticancer Agent Development Congress, 18 - 19 May 2015
- XI. **Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16F10 melanoma cell line**
KOÇAK F. E. , Erdoğan E., Özyiğit F., YERLİKAYA A.

Kongre & Lab Expo 2014, 16 - 20 September 2014

XII. The antiproliferation and antitumor activities of the 26S proteasome inhibitors

YERLİKAYA A., ERİN N.

Joint 4th EORTC Pathobiology Group Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009

XIII. The 26S proteasome one of the most critical players in cancer development

YERLİKAYA A.

The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 April 2014

XIV. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro

SARIMAHMUT M., CEVATEMRE B., ARI F., YERLİKAYA A., Dimas K., ULUKAYA E.

The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 April 2014

XV. Targeting the proteasome for the induction of apoptosis in cancer treatment

YERLİKAYA A.

EACR-Anticancer Agents Research Congress, 13 - 16 October 2011

XVI. Effect of proteasome inhibition on protein synthesis and eIF 2 phosphorylation

YERLİKAYA A.

1. Multidisipliner Kanser Araştırma Sempozyumu (uluslararası katılımlı), 12 - 15 March 2006

Supported Projects

Yerlikaya A., Tümer E., TUBITAK Project, Proteozom inhibitörü bortezomibe dirençli PC3 prostat hücrelerinde hücre ölüm modu ve PI3K/MAPK sinyal yollarının araştırılması, 2019 - 2021

Erin N., Yerlikaya A., TUBITAK Project, Investigation of the role of extracellular matrix proteins Fibulin-4 in metastatic breast cancer cells: interaction with TGF- β 1, LTBP-1 and BMP-1, 2018 - 2021

Tümer E., Yerlikaya A., TUBITAK Project, Bor içeren yeni sodyum bütirat türevlerinin CaCo-2 kolon ve 4T1 meme hücre hatlarındaki etkileri, 2019 - 2020

Yerlikaya A., Project Supported by Higher Education Institutions, Proteozom inhibitörü bortezomibe dirençli PC3 prostat kanseri hücre hattı eldesi ve çeşitli antineoplasiklere karşı hassasitenin belirlenmesi, 2017 - 2018

ÖZCURA F., YERLİKAYA A., Project Supported by Higher Education Institutions, Proteozom İnhibitörü Carfilzomib ve Çeşitli Antineoplastiklerin Y79 Retinoblastom Hücre Hattı Üzerindeki in Vitro Etkinlikleri, 2016 - 2017

YERLİKAYA A., Project Supported by Higher Education Institutions, Sıçanlarda Parsiyel Hepatektomi Sonrası Karaciğer Rejenerasyonuna Lösinin Mapk Erk Yolağı Üzerinden Etkisi, 2014 - 2017

YERLİKAYA A., TUBITAK Project, Olası Bir Anti Kanser Bileşik Terpiridin İçeren Palladyum II Sakkarinat Kompleksinin Pd Sac Terpy Sac Meme Kanser Kök Hücreleri Üzerindeki Sitotoksik Sitostatik Etkilerinin ve Mekanizmalarının Araştırılması, 2014 - 2016

YERLİKAYA A., TUBITAK Project, Proteozom İnhibitörü Bortezomib Ve Grp78 Bip İnhibitörü Bapta Nın Metastatik 4t1 Meme Kanseri Hücreleri Üzerindeki Kombine Etkisi, 2013 - 2016

Arslan O., Yerlikaya A., TUBITAK Project, Taraxacum officinale karahindiba ve Cornus mas kıvılcık bitkilerinin karşılaştırmalı B16F10 melanoma ve 4T1 meme kanseri hücre kültürlerine etkileri, 2014 - 2015

Arslan F., Yerlikaya A., TUBITAK Project, Muscari miller Arap sümbülü ve Plantago lanceolata sinir otu bitkilerinin karşılaştırmalı B16F10 melanoma ve 4T1 meme kanseri hücre kültürlerine etkileri, 2014 - 2015

YERLİKAYA A., TUBITAK Project, Proteozom inhibitörü Velcadein 4T1 kanser hücrelerinde uyardığı p53 bağımsız apoptozisin araştırılması, 2009 - 2012

YERLİKAYA A., TUBITAK Project, Proteozom inhibisyonunun meme ve melanoma kanser hücre dizileri üzerindeki etkileri, 2006 - 2009

Activities in Scientific Journals

Oncology Letters, Committee Member, 2018 - Continues

Memberships / Tasks in Scientific Organizations

Molecular Cancer Research Association, Member, 2011 - Continues

Scientific Refereeing

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, SCI Journal, August 2020

Experimental And Therapeutic Medicine, SCI Journal, January 2019

ONCOLOGY LETTERS, SCI Journal, March 2018

Citations

Total Citations (WOS):322

h-index (WOS):11

Invited Talks

Cellular Functions of the 26S Proteasome, Seminar, İhsan Doğramacı Bilkent Üniversitesi, Turkey, October 2009

Scholarships

Yüksek Öğretim Kurumu lisansüstü eğitim bursu, YOK, 1994 - 2002

Awards

Yerlikaya A., MOKAD's SPECIAL AWARD, Moleküler Kanser Araştırma Derneği (Mokad), May 2015

Yerlikaya A., MOKAD's SPECIAL AWARD, Moleküler Kanser Araştırma Derneği (Mokad), December 2012